The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Paltseva E.M.

Laboratoriia élektronnoĭ mikroskopii i immunogistokhimii Tsentralizovannogo patologoanatomicheskogo otdeleniia GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdravsotsrazvitiia Rossii

Sekacheva M.I.

Otdelenie khirurgii pecheni, zhelchnykh puteĭ i podzheludochnoĭ zhelezy Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Fedorov D.N.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Skipenko O.G.

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. B.V. Petrovskogo RAMN, Moskva

Impact of preoperative chemotherapy on the expression of apoptosis factors in colorectal cancer liver metastases

Authors:

Paltseva E.M., Sekacheva M.I., Fedorov D.N., Skipenko O.G.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2014;76(4): 18‑23

Read: 1560 times

Contact the author
Table of contents

IMPACT OF PREOPERATIVE CHEMOTHERAPY ON THE EXPRESSION OF APOPTOSIS FACTORS IN COLORECTAL CANCER LIVER METASTASES
IMPACT OF PREOPERATIVE CHEMOTHERAPY ON THE EXPRESSION OF APOPTOSIS FACTORS IN COLORECTAL CANCER LIVER METASTASES

To cite this article:

Paltseva EM, Sekacheva MI, Fedorov DN, Skipenko OG. Impact of preoperative chemotherapy on the expression of apoptosis factors in colorectal cancer liver metastases. Russian Journal of Archive of Pathology. 2014;76(4):18‑23. (In Russ.)

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pathomorphosis of transplanted C6 glioma treated with a 1267 nm wave­length laser. Russian Journal of Archive of Pathology. 2026;(2):52-58
Alveolar ridge bone augmentation using gene-activated bone substitute: long-term clinical follow-up. Stomatology. 2025;(6-2):56-64
Evaluation of the predictive ability of cystatin C and solu­ble Fas-receptor for the ischemic events deve­lopment using a popu­lation-based biobank. Russian Journal of Preventive Medi­cine. 2026;(3):78-85
A study of vascular endo­thelial growth factor in urine for the diagnosis of retrograde ejaculation. Labo­ratory Service. 2026;(1):8-13
The path to inno­vation: therapy for meta­static colo­rectal cancer today and tomo­rrow (based on mate­rials from the 12th RUSSCO Conference “Tumors of the Gastrointestinal Tract”). P.A. Herzen Journal of Onco­logy. 2026;(3):112-117
Abstract:

Objective - to study the effects of cytotoxic and targeted anti-VEGF drugs on some mechanisms of apoptosis. Material and methods. The effects of cytotoxic and targeted anti-VEGF drugs on the expression of the apoptosis activators Bax and PML and the apoptosis inhibitor Bcl-2 were studied in the colorectal cancer (CRC) liver metastases; a comparison group comprised patients receiving no chemotherapy. Results. Immunohistochemical examination revealed lower Bax and PML expressions and higher Bcl-2 expression in the majority of untreated patients, suggesting the suppressed mechanisms triggering tumor cell apoptosis. Cytotoxic therapy resulted in a statistically significant rise in the expression of the apoptosis activator Bax (p=0.01), a reduction in the level of the apoptosis inhibitor Bcl-2 (р=0.04) and a slight increase in PML that controlled the induction of apoptosis. Adding an anti-VEGF agent to cytotoxic therapy exerted no statistically significant impact on Bax and Bcl-2, but caused more frequent positive PML expression than in the control and cytotoxic chemotherapy groups. Conclusion. Our study showed that cytotoxic and targeted anti-VEGF agents activate the apoptosis of tumor cells in the CRC liver metastases.

Keywords:

metastatic colorectal cancer
apoptosis
Bax
Bcl-2
PML
cytotoxic agents
VEGF

Authors:

Paltseva E.M.

Laboratoriia élektronnoĭ mikroskopii i immunogistokhimii Tsentralizovannogo patologoanatomicheskogo otdeleniia GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdravsotsrazvitiia Rossii

Sekacheva M.I.

Otdelenie khirurgii pecheni, zhelchnykh puteĭ i podzheludochnoĭ zhelezy Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Fedorov D.N.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Skipenko O.G.

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. B.V. Petrovskogo RAMN, Moskva

Close metadata

References:

  1. Shimuzu S., Iida S., Ishiguro M., Uetake H., Ishikawa T., Takagi Y. et al. Methylated BNIP3 gene in colorectal cancer prognosis. Oncol. Lett. 2010; 1: 865-72.
  2. Hayward R.L., Macpherson J.S., Cummings J., Monia B.P., Smyth J.F., Jodrell D.I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol. Cancer Ther. 2004; 3 (2): 169-78.
  3. Haug K., Kravik K.L., De Angelis P.M. Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-Fluorouracil. Anticancer Res. 2008; 28: 583-92.
  4. Pires I.M., Ward T.H., Dive C. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br. J. Pharmacol. 2010; 159: 1326-38.
  5. Roh S. A., Choi E.Y., Cho D.H., Yoon Y.S., Kim T.W., Kim Y.S., Kim J.C. Characterization of biological responses of colorectal cancer cells to anticancer regimens. J. Korean Surg. Soc. 2012; 83 (1): 21-9.
  6. Bogusz J., Majchrzak A., Mędra A., Cebula-Obrzut B., Robak T., Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig. Med. Dosw. (Online). 2013; 67: 107-18.
  7. Sperling J., Brandhorst D., Schäfer T., Ziemann C., Benz-Weiber A., Scheuer C. et al. Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin. Exp. Metastasis. 2013; 30: 447-55.
  8. Arango D., Wilson A.J., Shi Q., Corner G.A., Arañes M.J., Nicholas C. et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer. 2004; 91: 1931-46.
  9. Kikuchi M., Mikami T., Sato T., Tokuyama W., Araki K., Watanabe M. et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br. J. Cancer. 2009; 101: 116-23.
  10. Legarza K., Yang L.-X. New molecular mechanisms of action of camptothecin-type drugs. Anticancer Res. 2006; 26: 3301-6.
  11. Fujie Y., Yamamoto H., Ngan C.Y., Takagi A., Hayashi T., Suzuki R. et al. Oxaliplatin, a potent inhibitor of surviving, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn. J. Clin. Oncol. 2005; 35 (8): 453-63.
  12. Bendardaf R., Ristämaki R., Syrjänen K., Pyrhönen S. Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients. World J. Gastroenterol. 2008; 14 (40): 6218-23.
  13. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J. et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 2004; 96: 269-79.
  14. Zhou G.-B., Zhang J., Wang Z.-Y., Chen S.-J., Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil. Trans. R. Soc. B. 2007; 362: 959-71.
  15. Vincenzi B., Santini D., Perrone G., Graziano F., Loupakis F., Schiavon G. et al. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. J. Cell. Physiol. 2012; 227 (3): 927-33.
  16. Liu R., Ferguson B.D., Zhou Y., Naga K., Salgia R., Gill P.S. et al. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013; 13: 269-75.
  17. Pietrantonio F., Biondani P., Milione M., Melotti F., Bertarelli G., Perrone F. et al. Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. Clin. Transl. Oncol. 2013; 15 (7): 582-6.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.